LSI Segment Divestment

Manufacturing the Moderna COVID-19 Vaccine Supporting accelerated vaccine production to control the pandemic 10-year collaboration agreement with Moderna on mRNA platform, including the manufacture of the drug substance for Moderna COVID-19 Vaccine Eight months turnaround from contract negotiation to commencement of manufacture Demonstrates the commercial value of the Ibex Solutions offering (and pre-investment in facilities) Showcases Lonza's capability to address customer challenges of speed and scale 11

View entire presentation